

Company Overview

Monopar Therapeutics is a clinical-stage biotechnology company developing novel radiopharmaceuticals for oncology and a new treatment for Wilson Disease, a rare genetic disorder. Its pipeline includes radiopharmaceuticals targeting advanced solid tumors and late-stage ALXN1840, a treatment for Wilson Disease. The radiopharma programs targeting advanced cancers include clinical-stage MNPR-101-Zr for imaging, and for therapy, clinical-stage MNPR-101-Lu and late-preclinical stage MNPR-101-Ac. Monopar builds its drug development pipeline through in-house efforts and licensing of late preclinical and clinical-stage therapeutics, leveraging its scientific and clinical expertise to reduce risk and accelerate development.

Monopar Therapeutics Inc. Announces Pricing of \$135 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

Sep 23 2025, 11:08 PM EDT

Monopar Announces Journal of Hepatology Publishes Physicians' Letter to the Editor Demonstrating ALXN1840 Rapidly Improved Copper Balance in Wilson Disease Patients

Sep 23 2025, 11:07 PM EDT

Stock Overview

Symbol	MNPR
Exchange	Nasdaq
Market Cap	472.8m
Last Price	\$76.63
52-Week	\$4.50 - \$79.80

09/26/2025 08:00 PM EDT

Management Team

Chandler D. Robinson, MD MBA MSc

Co-Founder, Chief Executive Officer and Board Member

Christopher M. Starr, PhD

Co-Founder and Executive Chairman of the Board

Quan Vu

Chief Financial Officer, Principal Accounting Officer, and Principal Financial Officer

Monopar Therapeutics Inc.

1000 Skokie Blvd.
Suite 350
Wilmette, IL 60091

Disclaimer

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.